Tuberin and PRAS40 are anti-apoptotic gatekeepers during early human amniotic fluid stem-cell differentiation

Human Molecular Genetics

Volumn 21, Issue 5, 2012, Pages 1049-1061

  Fuchs, Christiane ^a   Rosner, Margit ^a   Dolznig, Helmut ^a   Mikula, Mario ^a   Kramer, Nina ^a   Hengstschl̈ger, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; CASPASE 3; MAMMALIAN TARGET OF RAPAMYCIN; PROLINE RICH AKT SUBSTRATE OF 40 KDA PROTEIN; PROLINE RICH PROTEIN; SMALL INTERFERING RNA; TUBERIN; UNCLASSIFIED DRUG;

AMNIOTIC FLUID STEM CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; DOWN REGULATION; EMBRYOID BODY; GENE PRODUCT; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; STEM CELL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMNIOTIC FLUID; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; DOWN-REGULATION; EMBRYOID BODIES; GERM LAYERS; HUMANS; PLURIPOTENT STEM CELLS; RNA, SMALL INTERFERING; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84856948713     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr535     Document Type: Article

References (48)

1. Prusa, A.R., Marton, E., Rosner, M., Bernaschek, G. and Hengstschläger, M. (2003) Oct4 expressing cells in human amniotic fluid: a new source for stem cell research? Hum. Reprod., 18, 1489-1493.
2. Aboushwareb, T. and Atala, A. (2008) Stem cells in urology. Nat. Clin. Pract. Urol., 5, 621-631.
3. Rosner, M., Mikula, M., Preitschopf, A., Feichtinger, M., Schipany, K. and Hengstschläger, M. (2011) Neurogenic differentiation of amniotic fluid stem cells. Amino Acids, doi 10.1007/s00726-011-0929-8.
4. De Coppi, P., Bartsch, G., Siddiqui, M.M., Xu, T., Santos, T.X., Perin, L., Mostoslavsky, G., Serre, A.C., Snyder, E.Y., Yoo, J.J. et al. (2007) Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotechnol., 25, 100-106.
5. Siegel, N., Rosner, M., Unbekandt, M., Fuchs, C., Slabina, N., Dolznig, H., Davies, J.A., Lubec, G. and Hengstschläger, M. (2010) Contribution of human amniotic fluid stem cells to renal tissue formation depends on mTOR. Hum. Mol. Genet., 19, 3320-3331.
6. Koike, M., Sakaki, S., Amano, Y. and Kurosawa, H. (2007) Characterization of embryoid bodies of mouse embryonic stem cells formed under various culture conditions and estimation of differentiation status of such bodies. J. Biosci. Bioeng., 104, 294-299.
7. Ungrin, M.D., Joshi, C., Nica, A., Bauwens, C. and Zandstra, P.W. (2008) Reproducible, ultra high-troughput formation of multicellular organization from single cell suspension-derived human embryonic stem cell aggregates. PLoS ONE, 3, e1565.
8. Valli, A., Rosner, M., Fuchs, C., Siegel, N., Bishop, C.E., Dolznig, H., Mädel, U., Feichtinger, W., Atala, A. and Hengstschläger, M. (2010) Embryoid body formation of human amniotic fluid stem cells depends on mTOR. Oncogene, 29, 966-977.
9. Rosner, M., Siegel, N., Fuchs, C., Slabina, N., Dolznig, H. and Hengstschläger, M. (2010) Efficient siRNA-mediated prolonged gene silencing in human amniotic fluid stem cells. Nat. Protoc., 5, 1081-1095.
10. Yang, Q. and Guan, K.-L. (2007) Expanding mTOR signaling. Cell Res., 17, 666-681.
11. Wang, X. and Proud, C.G. (2009) Nutrient control of TORC1, a cell-cycle regulator. Trends Cell Biol., 19, 260-267.
12. Sengupta, S., Peterson, T.R. and Sabatini, D.M. (2010) Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell, 40, 310-322.
13. Freilinger, A., Rosner, M., Krupitza, G., Nishino, M., Lubec, G., Korsmeyer, S.J. and Hengstschläger, M. (2006) Tuberin activates the proapoptotic molecule BAD. Oncogene, 25, 6467-6479.
14. Grusch, M., Polgar, D., Gfatter, S., Leuhuber, K., Huettenbrenner, S., Leisser, C., Fuhrmann, G., Kassie, F., Steinkellner, H., Smid, K. et al. (2002) Maintenance of ATP favours apoptosis over necrosis triggered by benzamide riboside. Cell Death Differ., 9, 169-178.
15. Armstrong, J.F., Pritchard-Jones, K., Bickmore, W.A., Hastie, N.D. and Bard, J.B. (1993) The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mech. Dev., 40, 85-97.
16. Cai, J., Chen, J., Liu, Y., Miura, T., Luo, Y., Loring, J.F., Freed, W.J., Rao, M.S. and Zeng, X. (2006) Assessing self-renewal and differentiation in human embryonic stem cell lines. Stem. Cells, 24, 516-530.
17. Ren, X.W., Liang, M., Meng, X., Ye, X., Ma, H., Zhao, Y., Guo, J., Cai, N., Chen, H.Z., Ye, S.L. and Hu, F. (2006) A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. Cancer Gene Ther., 13, 159-168.
18. Ogden, S.K., Lee, K.C., Wernke-Dollries, K., Stratton, S.A., Aronow, B. and Barton, MC. (2001) p53 targets chromatin structure alteration to repress alpha-fetoprotein gene expression. J. Biol. Chem., 276, 42057- 42062.
19. Mahller, Y.Y., Williams, J.P., Baird, W.H., Mitton, B., Grossheim, J., Saeki, Y., Cancelas, J.A., Ratner, N. and Cripe, T.P. (2009) Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE, 4, e4235.
20. Loeb, D.M., Evron, E., Patel, C.B., Sharma, P.M., Niranjan, B., Buluwela, L., Weitzman, S.A., Korz, D. and Sukumar, S. (2001) Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res., 61, 921-925.
21. Unbekandt, M. and Davies, J.A. (2010) Dissociation of embryonic kidneys followed by reaggregation allows the formation of renal tissues. Kidney Int., 77, 407-416.
22. Rosner, M., Freilinger, A., Hanneder, M., Fujita, N., Lubec, G., Tsuruo, T. and Hengstschläger, M. (2007) p27Kip1 localization depends on the tumor suppressor protein tuberin. Hum. Mol. Genet., 16, 1541-1556.
23. Neuman, N.A. and Henske, E.P. (2011) Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis. EMBO Mol. Med., 3, 1-12.
24. Sancak, Y., Thoreen, C.C., Peterson, T.R., Lindquist, R.A., Kang, S.A., Spooner, E., Carr, S.A. and Sabatini, D.M. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell, 25, 903-915.
25. Wang, L., Harris, T.E., Roth, R.A. and Lawrence, J.C. Jr. (2007) PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J. Biol. Chem., 282, 20036-20044.
26. Thedieck, K., Polak, P., Kim, M.L., Molle, K.D., Cohen, A., Jenö, P., Arrieumerlou, C. and Hall, M.N. (2007) PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS ONE, 2, e1217.
27. Fonseca, B.D., Smith, E.M., Lee, V.H., MacKintosh, C. and Proud, C.G. (2007) PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J. Biol. Chem., 282, 24514-24524.
28. Oshiro, N., Takahashi, R., Yoshino, K., Tanimura, K., Nakashima, A., Eguchi, S., Miyamoto, T., Hara, K., Takehana, K., Avruch, J., Kikkawa, U. and Yonezawa, K. (2007) The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J. Biol. Chem., 282, 20329-20339.
29. Choo, A.Y., Yoon, S.O., Kim, S.G., Roux, P.P. and Blenis, J. (2008) Rapamycin differently inhibits S6Ks and 4E-BP1 to mediate cell type-specific repression of mRNA translation. Proc. Natl Acad. Sci. USA, 105, 17414-17419.
30. Sarbassov, D.D., Ali, S.M., Sengupta, S., Sheen, J.H., Hsu, P.P., Bagley, A.F., Markhard, A.L. and Sabatini, D.M. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell, 22, 159-168.
31. Rosner, M. and Hengstschläger, M. (2008) Cytoplasmic and nuclear distribution of the protein complex mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum. Mol. Genet., 17, 2934-2948.
32. Zhou, J., Su, P., Wang, L., Chen, J., Zimmermann, M., Genbacev, O., Afonja, O., Horne, M.C., Tanaka, T., Duan, E. et al. (2009) mTOR supports long-term self-renewal and suppresses mesoderm and endoderm activites of human ambryonic stem cells. Proc. Natl Acad. Sci. USA, 106, 7840-7845.
33. Rosner, M., Hanneder, M., Siegel, N., Valli, A., Fuchs, C. and Hengstschläger, M. (2008) The mTOR pathway and its role in human genetic diseases. Mutat. Res. Rev. Mutat. Res., 659, 284-292.
34. Nascimento, E.B.M. and Ouwens, D.M. (2009) PRAS40: Target or modulator of mTORC1 signalling and insulin action? Arch. Physiol. Biochem., 115, 163-175.
35. Onda, H., Lueck, A., Marks, P.W., Warren, H.B. and Kwiatkowski, D.J. (1999) Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest., 104, 687-695.
36. Kobayashi, T., Minowa, O., Kuno, J., Mitani, H., Hino, O. and Noda, T. (1999) Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res., 59, 1206-1211.
37. Gangloff, Y.G., Mueller, M., Dann, S.G., Svoboda, P., Sticker, M., Spetz, J.F., Um, S.H., Brown, E.J., Cereghini, S., Thomas, G. and Kozma, S.C. (2004) Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell Biol., 24, 9508-9516.
38. Murakami, M., Ichisaka, T., Maeda, M., Oshiro, N., Hara, K., Edenhofer, F., Kiyama, H., Yonezawa, K. and Yamanaka, S. (2004) mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell Biol., 24, 6710-6718.
39. Hentges, K.E., Sirry, B., Gingeras, A.C., Sarbassov, D., Sonenberg, N., Sabatini, D. and Peterson, A.S. (2001) FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse. Proc. Natl Acad. Sci. USA, 98, 13796-13801.
40. Jirmanova, L., Afanassieff, M., Gobert-Gosse, S., Markossian, S. and Savatier, P. (2002) Differential contributions of ERK and PI3-kinase to the regulation of cyclin D1 expression and to the control of the G1/S transition in moue embryonic stem cells. Oncogene, 21, 5515-5528.
41. Kawasome, H., Papst, P., Webb, S., Keller, G.M., Johnson, G.L., Gelfand, E.W. and Terada, N. (1998) Targeted disruption of p70(S6K) defines its role in protein synthesis and rapamycin sensitivity. Proc. Natl Acad. Sci. USA, 95, 5033-5038.
42. Madhunapantula, S.V., Sharma, A. and Robertson, G.P. (2007) PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res., 67, 3626-3636.
43. Inoki, K., Zhu, T. and Guan, K-L. (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell, 115, 577-590.
44. Freilinger, A., Rosner, M., Hanneder, M. and Hengstschläger, M. (2008) Ras mediates cell survival by regulating tuberin. Oncogene, 27, 2072-2083.
45. Ghosh, S., Tergaonkar, V., Rothlin, C.V., Correa, R.G., Bottero, V., Bist, P., Verma, I.M. and Hunter, T. (2006) Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival. Cancer Cell, 10, 215-226.
46. Kang, Y.J., Lu, M.K. and Guan, K-L. (2011) The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis. Cell Death Differ., 18, 133-144.
47. Thoreen, C.C., Kang, S.A., Chang, J.W., Liu, Q., Zhang, J., Gao, Y., Reichling, L.J., Sim, T., Sabatini, D.M. and Gray, N.S. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem., 284, 8023-8032.
48. Rosner, M., Hofer, K., Kubista, M. and Hengstschläger, M. (2003) Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38. Oncogene, 22, 4786-4798.